November 26, 2014 10:46 AM ET


Company Overview of Stemedica Cell Technologies, Inc.

Company Overview

Stemedica Cell Technologies, Inc., a biopharmaceutical company, engages in the development and manufacture of adult stem cells and stem cell factors for research institutions and hospitals for pre-clinical and clinical studies. The company was incorporated in 2005 and is based in San Diego, California with a subsidiary location in Lausanne, Switzerland.

5375 Mira Sorrento Place

Suite 100

San Diego, CA 92121

United States

Founded in 2005





Key Executives for Stemedica Cell Technologies, Inc.

Vice Chairman and Chief Executive Officer
Age: 67
Executive Chairman
Age: 67
Chief Financial Officer
Age: 66
Chief Regulatory & Clinical Development Officer
Compensation as of Fiscal Year 2014.

Stemedica Cell Technologies, Inc. Key Developments

Stemedica Cell Technologies Appoints Mahendra Rao to its Scientific and Medical Advisory Board

Stemedica Cell Technologies Inc. welcomed to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D. As a Founding Director of the National Institute of Health (NIH) Center for Regenerative Medicine (CRM), he has built the Center into a world-class organization recognized for its excellence in the clinical translation of stem cell technology, and his expertise will help Stemedica shape its strategy to meet global demand for its stem cell technology.

Stemedica Cell Technologies, Inc. Appoints Craig W. Carlson as Chief Financial Officer, Effective March, 2014

Stemedica Cell Technologies, Inc. announced that Craig W. Carlson has been appointed the company's Chief Financial Officer effective March, 2014. Craig Carlson brings 34 years of financial, accounting, investor relations, and operational experience specifically in the biotech and biopharmaceutical industries to his role at Stemedica.

Stephen E. Epstein to Head Scientific & Medical Advisory Board for Stemedica Cell Technologies, Inc.'s Cardiology Division

Stemedica Cell Technologies, Inc. announced that cardiologist Stephen E. Epstein, MD, Director of Translational Research of the MedStar Heart Institute, Washington Hospital Center, has accepted the position of Chairman of Stemedica’s Scientific and Medical Advisory Board for the Company’s Cardiology Division. Dr. Epstein served for over 30 years as Chief of the Cardiology Branch of the National Heart, Lung and Blood Institute (NHLBI) in Bethesda, Maryland. Dr. Epstein is currently Vice-Chairman of the Data Safety Management Board (DSMB) for Programs of Excellence in Gene and Cell Therapy for the NHLBI, and had served as Chairman of the DSMB for Specialized Centers for Clinically Oriented Research in Cardiac Dysfunction and Disease until the completion of that NHLBI effort.

Similar Private Companies By Industry

Company Name Region
Stemedica Cell Technologies, Inc. United States
Keraplast Technologies Ltd. United States
LifeCell Corporation United States
Click Therapeutics, Inc. United States
Lifecore Biomedical, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Stemedica Cell Technologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at